Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

AMAG PHARMACEUTICALS, INC. (AMAG)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
13.525(c) 13.7(c) 13.9(c) 17.95(c) 18.5(c) Last
1 782 802 913 070 1 127 118 11 653 074 2 874 277 Volume
+4.44% +1.29% +1.46% +29.14% +3.06% Change
More quotes
Financials ($)
Sales 2017 615 M
EBIT 2017 -134 M
Net income 2017 -215 M
Debt 2017 497 M
Yield 2017 -
Sales 2018 523 M
EBIT 2018 -13,1 M
Net income 2018 -110 M
Debt 2018 528 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1,87x
EV / Sales2018 2,26x
Capitalization 653 M
More Financials
Company
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia.It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of AMAG Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMAG PHARMACEUTICALS, INC.
04:10pANTARES PHARMA : Announces FDA Approval Of Partner's Product Utilizing Our Quick..
AQ
02/17ANTARES PHARMA : and AMAG surge after FDA approves jointly developed injector
AQ
02/16AMAG PHARMACEUTICALS : Announces FDA Approval of Makena Subcutaneous Auto-Inject..
AQ
02/16ANTARES PHARMA : Announces FDA Approval of Partner`s Product Utilizing Our Quick..
AQ
02/15AMAG PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Regul..
AQ
02/15ANTARES PHARMA : Announces FDA Approval of Partners Product Utilizing Our QuickS..
AQ
02/15AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone c..
GL
02/05AMAG PHARMACEUTICALS,INC. (NASDAQ : AMAG) Files An 8-K Other Events
AQ
02/05AMAG PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (for..
AQ
02/05AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Applicat..
GL
More news
Sector news : Pharmaceuticals - NEC
09:28pBASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
06:25pUK shares retreat as Reckitt disappoint
RE
05:44pReckitt shares sink on missed profit, vague outlook
RE
01:17pNOVARTIS : Correction to Novartis CEO story
DJ
12:40pStronger European Earnings Augur More M&A, Higher Dividends
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
03:33pJefferies Group Sets AMAG Pharmaceuticals FY2022 Earnings Estimates at ($0.44.. 
11:17aAMAG Pharmaceuticals $AMAG Upgraded to “Buy” by Janney Montgomery Scott  
02/17AMAG Pharmaceuticals, Inc. to Post FY2019 Earnings of -$2.19 Per Share, Canto.. 
02/17AMAG Pharmaceuticals $AMAG Upgraded to Buy by Janney Montgomery Scott  
02/17$AMAG - AMAG Pharmaceuticals Sees Unusually Large Options Volume #AMAG  
More tweets
Qtime:46
News from SeekingAlpha
02/16Biotech Forum Daily Digest For January 16th 
02/15YOUR DAILY PHARMA SCOOP : Shire Looks Attractive, Omeros Data, Axovant Restructu.. 
02/15Midday Gainers / Losers (2/15/2018) 
02/15HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (2/15/2018) 
02/15PREMARKET GAINERS AS OF 9 : 05 am (02/15/2018) 
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | AMAG | US00163U1060 | 4-Traders
Technical analysis trends AMAG PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 18,5 $
Spread / Average Target 0,00%
EPS Revisions
Managers
NameTitle
William K. Heiden President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles Chief Financial Officer, Treasurer & Senior VP
Julie Krop Chief Medical Officer & SVP-Regulatory Affairs
Nathan McBride Chief Information Officer & Senior VP-Innovation
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, INC.4.91%491
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572